NCT04095858 2023-02-08CATHYOncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 3 Terminated11 enrolled 10 charts
NCT00003056 2021-05-06Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell TransplantationTakedaPhase 3 Terminated105 enrolled
NCT00081055 2014-12-04OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic MalignanciesMesoblast, Ltd.Phase 2 Withdrawn